Targeting ovarian cancer’s supporting cells to avoid relapse

Why is it important for us to fund this research?

Every woman being treated for ovarian cancer fears the disease returning, knowing that the odds are stacked against them.

Despite enduring surgery and chemotherapy, a staggering 7 in 10 women face it coming back. This relapse is a major reason why less than half of women survive five years after diagnosis.

Despite enduring surgery and chemotherapy, a staggering 7 in 10 women face recurrence of ovarian cancer.

Professor Iain McNeish, the director of our Research Centre, has identified three potential drugs that could stop the cancer coming back after treatment. His approach targets immune cells that help the cancer grow, spread and resist treatment.

We are funding Iain and his team to test these drugs on samples in the laboratory that women with ovarian cancer generously donated.

What would this mean for women with ovarian cancer?

If these experiments are successful, the most promising drugs can progress towards clinical trials. These trials would test if the drugs are safe and effective, giving women a fighting chance to beat the disease and prevent relapse.

This is one of the biggest challenges in ovarian cancer care and has the potential to save thousands of lives.

Imagine having just one wish: more time with those you love. For women battling ovarian cancer, this is the one wish that burns brighter than any other. Read about the research projects we're funding to help make that wish come true.

Your donation can fuel groundbreaking research that aims to grant women more time with their loved ones.